Tackling Drug Resistance: New Approaches Offer Hope for Patients with Difficult-to-Treat Rheumatoid Arthritis.Persistent inflammation and resistance to common medicines remain major challenges for rheumatoid arthritis patients, prompting researchers to explore personalised treatments and innovative therapies.
Rheumatoid arthritis (RA), a chronic inflammatory disease that affects the joints, remains difficult to manage in some patients because their bodies stop responding effectively to medicines. Around 6% to 21% of people with the condition develop difficult-to-treat RA, continuing to experience inflammation and reduced physical function despite trying several treatments.
According to the available research, resistance to methotrexate, a commonly used frontline medicine, occurs in around 30% to 50% of cases. Resistance to biologic medicines is also reported in approximately 30% to 40% of patients. Understanding why these treatments fail is becoming increasingly important for doctors seeking better disease control.
Why do medicines stop working?
One major reason for treatment failure is the way cells absorb and remove medicines. In some patients, cellular transport problems prevent enough methotrexate from entering affected cells. At the same time, certain proteins push the medicine out, reducing its effectiveness.
Changes in cellular metabolism and gene activity can also keep joint tissues in an aggressive inflammatory state, making the disease harder to control.
Biologic medicines face another challenge: the immune system may produce anti-drug antibodies that reduce their effectiveness or speed up their removal from the body. In addition, inflammation can continue through alternative immune pathways, even when a particular treatment blocks one pathway.
New treatments offer fresh hope
Researchers are exploring several approaches to overcome drug resistance. These include CAR T-cell therapies designed to remove harmful immune cells, specially engineered nanocarriers that improve drug delivery, and treatments targeting multiple inflammatory pathways.
Low-dose interleukin-2 therapy, which aims to increase regulatory T cells, and vagus nerve stimulation are also being investigated as potential approaches.
Experts highlight the importance of checking treatment adherence, confirming the diagnosis and understanding the reasons behind treatment failure before changing medicines.
Future advances in multi-omics testing could help doctors identify individual disease patterns and select treatments accordingly.Although these emerging approaches require further research and clinical validation, personalised treatment strategies may offer new hope for patients struggling with difficult-to-treat rheumatoid arthritis.
For more health-related news
